Fig 3. A1C responses to oral glucose-lowering drugs among people with young- and usual-onset type 2 diabetes.

These insulin-naive individuals were observed during the first decade after diabetes diagnosis (population cohort, Hong Kong Diabetes Surveillance Database, 2002–2016). Sample sizes (number of A1C measurements) are indicated for each combination. Error bars indicate 95% confidence intervals. Differences between young- and usual-onset type 2 diabetes were statistically significant across all combinations (omnibus test p < 0.001). A, acarbose; D, dipeptidyl peptidase-4 inhibitor; M, metformin; S, sulfonylurea; T, thiazolidinedione.